SEC Form 6-K filed by Compugen Ltd.
$CGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2024
Commission File Number 000-30902
COMPUGEN LTD.
(Translation of registrant’s name into English)
26 Harokmim Street
Holon 5885849, Israel
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
Compugen Ltd.
On or about August 5, 2024, Compugen Ltd. (the “Company”) took action to distribute copies of its proxy statement to its shareholders and to mail to its
shareholders of record a proxy statement for an annual general meeting of shareholders to be held on Thursday, September 12, 2024, at 6:00 PM (Israel time) in Israel.
A copy of the notice of 2024 annual general meeting of shareholders of the Company, proxy statement and proxy card are attached to this Form 6-K as Exhibit 99.1.
The information contained in this Form 6-K is hereby incorporated by reference into the Company’s Registration Statements on Form F-3, File No. 333-270985.
Exhibits
|
Exhibit
Number
|
Description of Exhibit
|
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
COMPUGEN LTD.
|
||
|
|
|||
|
Date: August 5, 2024
|
By:
|
/s/ Eran Ben Dor
|
|
|
|
|
Eran Ben Dor
General Counsel
|
|